Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Withdrawn Phase 4 Interventional

VA Aripiprazole vs Esketamine for Treatment Resistant Depression

ClinicalTrials.gov ID: NCT05554627

Public ClinicalTrials.gov record NCT05554627. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

VA Aripiprazole vs. Esketamine for Treatment of Depression VAST-D II

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an open-label, parallel-group, randomized clinical trial of up to 6 months treatment of adjunctive intranasal (IN) esketamine (ESK) vs. adjunctive aripiprazole (ARI) in Veterans with unipolar Treatment Resistant Depression (TRD). This study will assess the efficacy, safety, and acceptability of adjunctive IN ESK in comparison to ARI, one of the best studied and most widely used adjunctive therapies for TRD. The primary hypothesis is that participants receiving adjunctive IN ESK will be significantly more likely to achieve remission after six weeks of treatment as compared to those who receive adjunctive ARI. Depressive symptoms will be assessed by central raters (CR), blinded to treatment assignment, using the clinician rated version of the Quick Inventory of Depressive Symptomatology (QIDS-C16), a well-validated tool that is commonly used and is easily translated across other depression inventory scales. The study is powered to detect an absolute difference in remission rates of 10%, or larger, at 6 weeks. Additional outcomes of interest include symptom reduction across 6 months of randomized therapy, side effects and other tolerability indices, attrition rates and measures of quality of life and cost-effectiveness.

Study identification

NCT ID
NCT05554627
Recruitment status
Withdrawn
Study type
Interventional
Phase
Phase 4
Enrollment
Not listed

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 74 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 26, 2023
Primary completion
Oct 26, 2023
Completion
Oct 26, 2023
Last update posted
Jan 4, 2024

2023

United States locations

U.S. sites
26
U.S. states
20
U.S. cities
25
Facility City State ZIP Site status
Tuscaloosa VA Medical Center, Tuscaloosa, AL Tuscaloosa Alabama 35404
Phoenix VA Health Care System, Phoenix, AZ Phoenix Arizona 85012
Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR Little Rock Arkansas 72205-5484
VA Long Beach Healthcare System, Long Beach, CA Long Beach California 90822
VA Palo Alto Health Care System, Palo Alto, CA Palo Alto California 94304-1290
VA San Diego Healthcare System, San Diego, CA San Diego California 92161
Rocky Mountain Regional VA Medical Center, Aurora, CO Aurora Colorado 80045
VA Connecticut Healthcare System West Haven Campus, West Haven, CT West Haven Connecticut 06516-2770
CERC (VISN1, West Haven, CT) West Haven Connecticut 06516
Atlanta VA Medical and Rehab Center, Decatur, GA Decatur Georgia 30033
Edward Hines Jr. VA Hospital, Hines, IL Hines Illinois 60141-5000
Richard L. Roudebush VA Medical Center, Indianapolis, IN Indianapolis Indiana 46202-2884
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA Boston Massachusetts 02130
Minneapolis VA Health Care System, Minneapolis, MN Minneapolis Minnesota 55417
Kansas City VA Medical Center, Kansas City, MO Kansas City Missouri 64128
New Mexico VA Health Care System, Albuquerque, NM Albuquerque New Mexico 87108-5153
Asheville VA Medical Center, Asheville, NC Asheville North Carolina 28805
Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC Salisbury North Carolina 28144
Cincinnati VA Medical Center, Cincinnati, OH Cincinnati Ohio 45220
Louis Stokes VA Medical Center, Cleveland, OH Cleveland Ohio 44106
Jackson C. Montgomery VA Medical Center, Muskogee, OK Muskogee Oklahoma 74401
Philadelphia MultiService Center, Philadelphia, PA Philadelphia Pennsylvania 19106
VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA Pittsburgh Pennsylvania 15240
Michael E. DeBakey VA Medical Center, Houston, TX Houston Texas 77030
Salem VA Medical Center, Salem, VA Salem Virginia 24153
William S. Middleton Memorial Veterans Hospital, Madison, WI Madison Wisconsin 53705

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05554627, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 4, 2024 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05554627 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →